Novo Nordisk reports oral semaglutide data in children and teens with type 2 diabetes
If it pans out, an oral GLP-1 could give children and teens with type 2 diabetes a pill option, but no pediatric study results or regulatory timeline have been released yet.
Novo Nordisk has reported data suggesting that oral semaglutide could become the first oral GLP-1 receptor agonist therapy for children and adolescents with type 2 diabetes, according to an announcement dated April 23, 2026 [1]. The study's size, the doses tested and the actual results have not been reported, so how much the drug lowered blood sugar in this age group is not yet known [1].
Where semaglutide stands in the US
Semaglutide is approved in the United States under several brand names, all of them for adults. Ozempic injection was first approved December 5, 2017, for adults with type 2 diabetes [1]. Rybelsus, an oral tablet, followed on September 20, 2019 [1]. Wegovy injection was approved June 4, 2021, for weight reduction in obesity and overweight [1]. A reformulated Rybelsus, called the R2 formulation, was approved December 9, 2024, and was rebranded as Ozempic tablets on January 30, 2026 [1]. Wegovy tablets were approved December 22, 2025 [1].
The approved uses listed for these products cover type 2 diabetes, reduction of major cardiovascular events, reduction of worsening kidney disease in type 2 diabetes, weight reduction, and noncirrhotic metabolic dysfunction-associated steatohepatitis [1]. None of the listed indications is for children or adolescents [1].
Ozempic tablets are taken once daily in the morning on an empty stomach, while Ozempic injection is given once weekly at any time of day, with or without meals [1]. Tablet strengths differ by product: Rybelsus comes in 3 mg, 7 mg and 14 mg tablets, the R2 formulation now sold as Ozempic tablets comes in 1.5 mg, 4 mg and 9 mg, and Wegovy tablets come in 1.5 mg, 4 mg, 9 mg and 25 mg [1]. Ozempic injection pens deliver 0.25 mg, 0.5 mg, 1 mg or 2 mg per injection [1].
All semaglutide products carry a boxed warning for thyroid C-cell tumors. Other warnings and precautions include acute pancreatitis, diabetic retinopathy complications, low blood sugar, acute kidney injury from volume depletion, severe gastrointestinal reactions, serious allergic reactions, acute gallbladder disease, and pulmonary aspiration during general anesthesia or deep sedation [1]. Common side effects reported in at least 5 percent of patients include nausea, vomiting, diarrhea, abdominal pain and constipation; the oral products also list decreased appetite [1].
Why it matters for patients
Families managing type 2 diabetes in a child or teenager currently have no approved GLP-1 option, based on the indications listed for these medicines [1]. An oral version would avoid injections, which matters for young patients and for caregivers who administer treatment. A pill also travels more easily than a pen that needs refrigeration and needles, though no information has been released about how an oral form would be packaged or priced for this age group [1].
Several questions remain open. Whether the reported data come from a randomized trial, how long children were followed, and whether the safety profile in young people resembles the adult profile have not been reported [1]. The FDA has not acted on any pediatric application for oral semaglutide, and no submission date has been disclosed [1].
What happens next
No date has been given for a regulatory filing or an FDA decision on oral semaglutide in children and adolescents [1]. Separately, Novo Nordisk said in February 2026 that the Ozempic pill would become available in the US in the second quarter of 2026 [1]. Wegovy tablets, approved December 22, 2025, remain indicated for adults only [1].
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.